Skip to main content
Skip to footer
Sign in to read the full text
The document summary and details above are public. The full text is available to signed-in accounts.
States / Minnesota / Bill text
Bill text
Introduction
SF 2645 — Formulary Committee members with a potential conflict of interest participation in committee communications and discussions authorization provision, public comment process for recommendations to the Formulary Committee development by the commissioner of human services requirement provision, and Minnesota Rare Disease Advisory Council expertise sought by the Formulary Committee requirement provision
SF 2645 (Introduction)
Introduction text of SF 2645.